EXEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Exelixis Inc (EXEL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown solid financial growth and maintains a leading position in its market, the lack of immediate positive trading signals, neutral trading sentiment, and mixed analyst ratings suggest waiting for a clearer entry point. The stock's current price is close to its resistance levels, and there are no significant catalysts to drive immediate growth.
The technical indicators are mixed. The MACD is positive but contracting, suggesting waning momentum. RSI is neutral at 51.64, indicating no clear overbought or oversold condition. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its pivot level of 44.647, with resistance at 45.709 and support at 43.585.
The company plans to launch next-gen cancer therapies within five years, which could drive future growth. Financials show strong YoY growth in revenue (5.63%), net income (74.84%), and EPS (83.33%) in Q4 2025.
Analyst sentiment is mixed, with some firms lowering price targets due to competitive pressures from Merck's HIF-2alpha inhibitors. The stock has limited near-term upside potential, with a 70% chance of minor fluctuations (-2.5% in the next week, +1.16% in the next month). Gross margin has slightly declined (-0.93% YoY).
In Q4 2025, Exelixis reported revenue of $598.66M, up 5.63% YoY. Net income increased significantly to $244.53M, up 74.84% YoY, and EPS rose to $0.88, an 83.33% increase YoY. However, gross margin decreased slightly to 95.58% (-0.93% YoY).
Analyst ratings are mixed. RBC Capital recently lowered its price target to $43, citing competitive pressures, while H.C. Wainwright raised its target to $54, maintaining a Buy rating. Other firms like Stifel and Barclays have issued Hold or Equal Weight ratings, with modest price target increases. The consensus reflects cautious optimism but no strong bullish sentiment.
